Bridget O'Keeffe

Bridget O’Keeffe most recently served as Senior Director of Clinical Development for Nektar Therapeutics, where she built and trained an oncology clinical science team and provided clinical development leadership in the development of company processes and policy

through interdepartmental, company-wide committees, working groups and initiatives. During her time with the company, Dr. O’Keeffe was also appointed Clinical Development Lead of the global Phase 3 randomized study for NKTR-214 (bempegaldesleukin) + OPDIVO® (nivolumab) in patients with renal cell carcinoma (RCC), for which she managed and led medical science strategy, Steering Committee and key opinion leader interactions, health authority/ethics committee responses, team training and clinical oversight of data collection and review.

Prior to Nektar, Bridget O’Keeffe held additional clinical development positions of increasing responsibility at Exelixis, Genentech, Clovis Oncology, Achaogen, and Calithera. In these roles, Dr. O’Keeffe served as medical monitor for multiple oncology studies in RCC, nonsmall cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC); provided scientific and medical expertise in the launch preparation for Rubraca® (rucaparib); participated on the clinical filing team for the new drug application (NDA) for ZEMDRI (plazomicin); and contributed to the early development of CABOMETYX ® (cabozantinib).

Bridget earned her Doctor of Philosophy in Molecular and Cell Biology at the University of California, Berkeley and her Bachelor of Arts in Biology and Asian Studies at Case Western Reserve University.